Journal Home
Search for

Volume 23, Issue 1, Pages 33-45 (March 2010)


View previous. 5 of 17 View next.

Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells

Rajendra N. Damle, Ph.D (Assistant Investigator, The Feinstein Institute for Medical Research)abemail address, Carlo Calissano, M.D. (Postdoctoral Fellow, The Feinstein Institute for Medical Research)aemail address, Nicholas Chiorazzi, M.D. (Investigator and Center Head, The Feinstein Institute for Medical Research)acdCorresponding Author Informationemail address

B cell-type chronic lymphocytic leukaemia (CLL) has long been considered a disease of resting lymphocytes. However, cell surface and intracellular phenotypes suggest that most CLL cells are activated cells, although only a small subset progresses beyond the G1 stage of the cell cycle. In addition, traditional teaching says that CLL cells divide rarely, and therefore the build-up of leukaemic cells is due to an inherent defect in cell death. However, in vivo labelling of CLL cells indicates a much more active rate of cell birth than originally estimated, suggesting that CLL is a dynamic disease.

Here we review the observations that have led to these altered views of the activation state and proliferative capacities of CLL cells and also provide our interpretation of these observations in light of their potential impact on patients.

a The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA

b Department of Medicine, NYU School of Medicine, NY, USA

c Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA

d Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA

Corresponding Author InformationCorresponding author. Tel.: +1 516 562 1090; Fax: +1 516 562 1011.

PII: S1521-6926(10)00009-5

doi:10.1016/j.beha.2010.02.001


View previous. 5 of 17 View next.